Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRONMAN intravenous iron in heart failure with iron deficiency
ISRCTN16403302Phase 4Completed
- Sponsor
- University of Glasgow
- Start
- Aug 2016
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Phase 4, randomised, open-label trial of ferric derisomaltose in heart failure (HF) and iron deficiency anemia (IDA) (2 arms), sponsored by University of Glasgow. Primary endpoint: Cardiovascular mortality or hospitalization for worsening heart failure. Started Aug 2016; status: completed.
02
Drugs
ferric derisomaltose
03
Conditions
heart failure (HF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on ISRCTN16403302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16403302.